

## Opportunity:

### Metastatic Colorectal Cancer (mCRC)

2nd

Colorectal cancer is the second leading cause of death among cancers.

15%

Only 15% of patients are alive at the five year mark from their diagnosis.

+ 16B

The global colorectal cancer market size was worth USD 16.11 billion in 2023.

Significant  
Unmet Need

Chemotherapy (Standard of Care) causes significant side effects that potentially limits both the dose and duration of treatment.

### BXQ-350 Highlights

- ➔ Completed adult and pediatric Phase 1 studies
- ➔ Demonstrated **excellent safety profile** conducive to combination treatment
- ➔ Activity seen across multiple tumor types – significant lifecycle expansion opportunity
- ➔ **Entering Phase 2 trial** of combination therapy in newly diagnosed **metastatic colorectal cancer (mCRC)**
  - Internal data readout 4Q23